accordance with
the anticipated timeline, the possibility that the market for the sale of
these new products may not develop as expected, the risks relating to
Align's ability to sustain or increase profitability or revenue growth in
future periods while controlling expenses, continued customer demand for
Invisalign and new products, changes in consumer spending habits as a
result of, among other tings, prevailing economic conditions, levels of
employment, salaries and wages and consumer confidence, the timing of case
submissions from our doctors within a quarter, acceptance of Invisalign by
consumers and dental professionals, Align's third party manufacturing
processes and personnel, foreign operational, political and other risks
relating to Align's international manufacturing operations, Align's ability
to protect its intellectual property rights, competition from manufacturers
of traditional braces and new competitors, Align's ability to develop and
successfully introduce new products and product enhancements, and the loss
of key personnel. These and other risks are detailed from time to time in
Align's periodic reports filed with the Securities and Exchange Commission,
including, but not limited to, its Annual Report on Form 10-K for the
fiscal year ended December 31, 2007, which was filed with the Securities
and Exchange Commission on February 26, 2008. Align undertakes no
obligation to revise or update publicly any forward-looking statements for
any reason.
Investor Relations Contact Press Contact
Shirley Stacy Shannon Mangum Henderson
Align Technology, Inc. Ethos Communication, Inc.
(408) 470-1150 (678) 540-9222
sstacy@aligntech.com align@ethoscommunication.com
ALIGN TECHNOLOGY, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPE
'/>"/>
SOURCE Align Technology, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 Related medicine news :1.
Align Technology Executive to Present at Upcoming Financial Conferences2.
WellPoint Announces Realignment of Core Businesses; Names New Executives3.
Align Technology to Announce Third Quarter 2007 Financial Results on October 24, 20074.
Align Technology, Inc. Earns PACE Approval From Academy of General Dentistry5.
Test gives insight into prognosis in patients with plasma cell malignancies, finds Mayo Clinic study6.
Threshold Pharmaceuticals Announces Corporate Realignment7.
Early Results of Phase 2 Trial of Perifosine (KRX-0401) for the Treatment of Recurrent Malignant Gliomas Presented at the 12th Annual Scientific Meeting of Society for Neuro-Oncology8.
Dallas Among the First to Offer Probiotic Supplement Align(R)9.
McGill researchers link enzyme to breast cancer malignancy10.
Breast Cancer Genes Also Raise Mens Risk for Malignancy11.
iNOS expression may links chronic biliary inflammation to malignant transformation